

LINCARE HOLDINGS INC.

LINCARE 

Forward-Looking Statements

Certain statements contained in this presentation constitute forward-looking statements. Such forward-looking statements are based on management's current expectations and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally, regionally and in the healthcare industry; demographic changes; industry consolidation; regulation and/or regulatory action affecting the Company; the ability to participate in managed care provider arrangements on acceptable terms; changes in Medicare, Medicaid and other third party payor payment policies or reimbursement rates, including those resulting from a shift from traditional reimbursement to managed care plans; liability and other claims asserted against the Company; competitive conditions; technological, pharmaceutical and other improvements that increase the cost of providing, or reduce the demand for, the Company's products and services; shortages of product, equipment or supplies, a breakdown in the distribution process or other factors that may increase the Company's cost of sales; changes in business strategy or development plans; the ability to attract and retain qualified personnel, including the impact on the Company's labor expenses resulting from a shortage of health care professionals; the availability to the Company of borrowed and/or equity capital on favorable terms; the availability of suitable acquisition opportunities and the length of time it takes to accomplish acquisitions; the Company's ability to integrate new businesses with its existing operations and efficient operation of the Company's existing and future operating facilities. Certain additional risks and uncertainties are discussed in the Company's filings with the Securities and Exchange Commission, including the Company's annual report on Form 10-K and quarterly reports on Form 10-Q. Do not rely on any forward-looking statement, as the Company cannot predict or control many of the factors that ultimately may affect its ability to achieve the results estimated. The Company makes no promise to update any forward-looking statement, whether as a result of changes in underlying factors, new information, future events or otherwise.



Investment Highlights

- Cost Efficient Operator
- Strong Free Cash Flow Generation
- Positioned to Adapt with Regulatory Environment
- Strong Demographic Trends
- Integrated IT Systems – One Platform
- Growing, Fragmented Industry

LINCARE 

Lincare Overview

- Leading Provider of Home Respiratory Services
- 1,056 Locations
- Recurring Revenue = 67% of Sales
- Respiratory Medications = 14% of Sales
- Sleep Revenue = 17% of Sales



Home Respiratory Drivers

- Long “Length of Stay” (12 to 24 months)
- Rising Incidence
- Core Patient Volume Growth Estimated at 6% Per Year Driven by Demographic Trends
- Reduced Hospital Capacity
- Patient Preference for Homecare

Drivers Support Continued Volume Growth

LINCARE+


COPD

16 Million People with Diagnosis of COPD in the United States

- 750,000+ Hospital Admissions
- Average Admission Cost - \$18,000
- Only Major Disease with Rising Incidence
- \$40 Billion in Healthcare Costs

Pulmonary Disease Incidence

COPD Hospital Discharges





Regulatory Landscape

- Deficit Reduction Act (DRA)
 - 2009 – 36 Month Cap on Oxygen Equipment
- Medicare Improvements Act (MIPPA)
 - Delays implementation of competitive bidding program until 2011
 - Administrative safeguards added to improve bid process
 - 9.5% Medicare price reductions in 2009
 - Repeal of ownership transfer of oxygen equipment

Industry Leading Market Share

- Local Market Focus
- Increasing Consolidation
- Efficient Operators Gaining Share
- Strong Operating Margins
- Local Players Disadvantaged by Regulatory Changes

Lincare has Consistently Grown Market Share Through Organic Growth and Selected Acquisitions



LINCARE 

Company Overview


LINCARE 

Lincare Strategy

- Focus on Organic Growth
- Selected Acquisitions
- Leverage Cost-Efficient Operating Platform
- Develop and Implement Specialized R.T. Programs
- Expand Sleep Platform

Largest Respiratory Provider

- 1,056 Centers
- Over 700,000 Patients in 48 States
- 34 Billing / Collections Offices
- 24 Pharmacies



Scale and Cost Efficiency Provide a Competitive Advantage in a Government Payor Market


LINCARE 

Internal Growth


- Face to Face Sales Calls
- Increased Sales Productivity
- Clinical Excellence
- Full Time Respiratory Therapists
- DeNovo Development
- Market Share Gains

Strong and Consistent Growth

Oxygen Customers



Internal Revenue Growth¹




LINCARE 

¹ Excluding Medicare price changes

Low Risk, Disciplined Growth Strategy

Revenue Growth (1)




Year	# of Acquisitions	Cost (\$MM)	Rev. Mult.
2003	13	\$154.0	1.7x
2004	26	104.8	1.7
2005	15	121.8	1.4
2006	10	72.5	0.9
2007	3	6.0	1.4
2008	3	22.0	1.5
Total	70	\$481.1	1.4x

(1) Growth excludes effect of Medicare pricing cuts of 0.0%, 4.7%, 14.8%, 4.6%, 1.6% and 4.6% in 2003, 2004, 2005, 2006, 2007 and 2008 respectively




Strong Operating Performance

Operating Income Margin



Note: Figures for nine months ended September 30, 2009 for Lincare; six months ended June 30, 2009 for AHOM and Rotech

FCF as % of Revenue ⁽¹⁾





(1) FCF (Free Cash Flow) = Cash from Operations minus Cap X;

LINCARE 

Effective Information Systems

- Proprietary, Single Platform
- Accounts Receivable Management
- Cost Control
- Effective Selling

2009 Accounts Receivable Management



Financial Overview

LINCARE 

Financial Highlights

(\$MM)	<u>Q3 2009</u>	<u>Q2 2009</u>	<u>Q1 2009</u>
Net Revenues	\$392.6	\$380.4	\$371.7
Net Income	36.0	33.5	26.0
EPS (\$/share)	\$0.53	\$0.49	\$0.36

LINCARE 


Operating Performance



**Lincare has Consistently
Demonstrated its Ability to Adapt to
Reimbursement Pressure**



Cashflow Expenditures



Cash Flow

(\$MM)	<u>2006</u>	<u>2007</u>	<u>2008</u>	9 Mos. <u>2009</u>
Cash from Operations	\$328.7	\$406.2	\$439.1	\$254.5
Cap Ex, Net	106.0	129.8	124.2	84.5
Free Cash Flow	222.7	276.4	314.9	170.0
F.C.F. / Share	\$2.32	\$3.27	\$4.30	\$2.45

LINCARE 

Capitalization

(\$MM)

	<u>12/31/06</u>	<u>12/31/07</u>	<u>12/31/08</u>	<u>9/30/09</u>
Total Assets	\$1,775.3	\$1,926.3	\$1,938.8	\$1,953.4
Total Debt	346.0	726.2	460.9	477.0
Stockholders' Equity	1,110.6	802.5	1,028.5	994.7
Leverage Ratio (Debt / EBITDA)	0.8x	1.5x	0.9x	1.3x

LINCARE 

Summary

- The Leading Respiratory Business
- Large and Growing Market
- Favorable Demographic Trends
- Organic and Strategic Growth Opportunities
- Integrated IT Systems
- Cost Efficient Organization
- Positioned to Adapt with Regulatory Environment
- Strong Free Cash Flow Generation

LINCARE 

LINCARE HOLDINGS INC.

LINCARE 